Petco (WOOF) Q2 2026 Earnings Call Transcript

Petco reported Q2 FY2026 net sales of $1.49 billion, up 0.05% year over year, with comparable sales rising 0.6% for a second consecutive positive quarter; normalized adjusted EBITDA was $115.4 million, above the prior year and outlook, while reported EBITDA reached $122.2 million including a $6.8 million tariff-refund benefit. The company reaffirmed FY2026 guidance for flat to 1.5% sales growth and $415 million to $430 million of adjusted EBITDA, despite expected fuel, tariff, and supply-chain pressures in the second half. Petco generated $60.8 million of year-to-date free cash flow and prepaid $75 million of debt, bringing nine-month debt reduction to $170 million, although dog-category softness and mid-single-digit-million sales disruption from Petco Perks redemptions remain headwinds.

Analysis

WOOF's near-term equity setup is less about the modest sales inflection than whether the market accepts a credible deleveraging path without sacrificing the turnaround. Incremental free cash flow and lower interest expense increase equity optionality disproportionately at this leverage level, but the earnings-quality issue remains material: core margin was essentially unchanged before the non-recurring benefit, while the company is simultaneously funding clearance, assortment resets and loyalty economics. The relevant Q3 test is therefore not headline EBITDA, but whether it is achieved with stable gross margin and without another deterioration in customer acquisition or redemption expense.

The strongest strategic asset is the owned veterinary footprint, which can convert clinical traffic into recurring prescription nutrition, services and autoship demand—categories less exposed to pure online price comparison. This creates a potential share-loss risk for Chewy (CHWY) in vet-led diet and fresh-food attachment, although Petco's advantage is not yet independently quantified through disclosed cross-shop conversion or hospital-level returns. Conversely, soft dog adoption is a multi-quarter drag on the highest-frequency consumables basket; cat mix and companion-animal strength improve category composition but are unlikely to offset a broad dog-demand recovery absent better traffic.

Consensus may overvalue early prototype-store results and the stated multichannel spending differential. A seven-store test can reflect selection, local marketing, or novelty effects, and fleetwide remodel returns are unproven. Upside becomes more credible over 6-18 months if management can demonstrate that low-capital format changes, autoship enrollment and veterinary productivity lift contribution margin before committing to new hospital growth in 2027; otherwise capex plus reinvestment could defer the anticipated equity rerating.

Key Decisions for Investors

• Maintain WOOF as a tactical long/watch position only through Q3 results (1-3 months), not a core turnaround holding: add only if Q3 EBITDA reaches or exceeds guidance while gross margin is stable sequentially excluding one-offs and debt declines further. A 15-20% upside rerating is plausible on proof of durable FCF; exit if sales miss the guided range or normalized EBITDA falls below $100 million.
• Prefer a market-neutral long WOOF / short CHWY basket over an outright WOOF long for 3-6 months, sized modestly. The thesis is that veterinary-led prescription diet, fresh-food attachment and in-store autoship can redirect higher-value recurring spend; stop out if CHWY's autoship/customer metrics accelerate while WOOF's consumables or digital momentum fails to improve.
• Do not underwrite a 2027 hospital-opening or broad-remodel catalyst yet. Set an alert for disclosure of hospital maturity curves, incremental store-format capex, four-wall returns and conversion of vet visits into food/autoship purchases; absent those data, any rally driven by prototype anecdotes should be sold into.
• Monitor freight/fuel costs and competitive pet-retail promotion weekly through year-end. Margin resilience is the key falsifier: renewed promotional intensity or input-cost inflation that forces guidance protection through investment cuts would undermine both the deleveraging narrative and the expected multiple expansion.